Kate Farms, Inc. specializes in the production of plant-based meal replacement shakes and tube feeding solutions, catering to individuals with various dietary and medical needs. Established in 2011 and headquartered in Santa Barbara, California, with an additional office in Waltham, Massachusetts, the company has become a leader in vegan nutrition. Its enteral formulas are designed for easy digestion and are free from common allergens such as dairy, soy, and gluten, making them suitable for a wide range of patients. Clinicians have reported positive outcomes, including reduced gastrointestinal intolerance and improved nutritional status for users. By combining advanced scientific research with natural ingredients, Kate Farms aims to enhance health and well-being, empowering caregivers, healthcare professionals, and patients to choose effective nutritional solutions. The company's commitment to quality ensures that everyone has access to nourishing options that promote overall health.
Reneo Pharmaceuticals develops therapies for patients with rare genetic mitochondrial diseases, which impact cellular metabolism and energy production. Founded in 2014 and based in San Diego, California, the company is focused on creating treatments that enhance mitochondrial function, thereby improving muscle health and overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes essential for energy metabolism and the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. By addressing the underlying metabolic deficiencies in these patients, Reneo aims to prevent muscle injury, weakness, and wasting, ultimately enhancing daily functioning for those with these orphan diseases.
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on developing peptide drugs aimed at treating dietary-related metabolic diseases, specifically obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics specializes in creating peptide-based GIP receptor antagonists that help monitor and manage these conditions by effectively reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to provide therapeutic solutions that address the growing challenges associated with metabolic disorders.
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.
VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on developing peptide drugs aimed at treating dietary-related metabolic diseases, specifically obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics specializes in creating peptide-based GIP receptor antagonists that help monitor and manage these conditions by effectively reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to provide therapeutic solutions that address the growing challenges associated with metabolic disorders.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. It develops and produces cultures, enzymes, probiotics, and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements, and even animal feed. All solutions are based on strong research and development competencies coupled with significant technology investments. Chr. Hansen has more than 2,500 employees in 30 countries and main production facilities in Denmark, France, USA, and Germany. It was founded in 1874 and is listed on Nasdaq Copenhagen.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.
BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.